MINNEAPOLIS--(BUSINESS WIRE)--Minneapolis-based Humanetics Corporation (Humanetics), a pharmaceutical company developing BIO 300 as a first-in-class radiation modulator, announced that Chief Medical Officer Dr. Michael Kurman will present at the 2018 BIO CEO & Investor Conference in New York City on Tuesday February 13, 2018 at 9:00 a.m. Eastern Time. Dr. Kurman’s presentation provides an overview of the company’s clinical development of BIO 300 as an adjuvant treatment to be used in the mitigation of toxicities associated with radiation therapy when administered to patients with solid tumors.
About Humanetics Corporation
Humanetics Corporation is a clinical-stage specialty pharmaceutical company engaged in accelerated discovery, development and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on radiation modulators for oncology and medical countermeasure uses. For more information, visit www.humaneticscorp.com.